---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-068530"
form_type: "8-K"
ticker: "GANX"
cik: "0001819411"
company_name: "Gain Therapeutics, Inc."
filed_at: "2025-07-17T23:59:59+00:00"
generated_at: "2026-05-18T05:59:42.945844+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Gain Therapeutics prices $7M public offering of common stock and warrants

## Summary
- Offering of 4,501,640 common shares and warrants to purchase 2,250,820 shares at $3.11 per set.
- Gross proceeds of $7.0M; net proceeds expected ~$6.3M after underwriting fees and expenses.
- Proceeds to fund clinical development of lead candidate GT-02287 for GBA1 Parkinson's disease.
- Warrants exercisable at $1.65 per share, immediately exercisable, expire in 5 years.
- Newbridge Securities sole book-runner; closing expected July 17, 2025.

## SEC filing metadata
- accession: 0001104659-25-068530
- form_type: 8-K
- ticker: GANX
- cik: 0001819411
- company_name: Gain Therapeutics, Inc.
- filed_at: 2025-07-17T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819411/000110465925068530/0001104659-25-068530-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819411/000110465925068530/tm2521066d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-068530
- JSON: https://secwatch.observer/filing/0001104659-25-068530.json
- Plain text: https://secwatch.observer/filing/0001104659-25-068530.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.